Joint Formulary & PAD

Formulary Search

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Search

A-Z of Drugs : A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

A-Z of Drugs

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

A to Z of Drugs : O

Records returned : 96 (on 16 Jul 2025 at 18:27:23).

Show Icon and Status Keys

Drug
Indication
Status
Restrictions/Comments
Formulary Status
Links
Status :
Red
Formulations :
  • Tablets
Restrictions / Comments:

Important
Dose adjustment and monitoring in pre-existing moderate / severe hepatic impairment. NHSE specialised commissioning - RSFT only.
 
Links :
NHSE
NICE
R
SPC
Indication :
Status :
Red
Formulations :
  • Infusion
Restrictions / Comments:

Important

ASPH are the only Surrey Heartlands Trust commissioned to provide this.

 
Links :
NHSE
SPC
Indication :
Status :
Red
Formulations :
  • Intravitreal injection
Restrictions / Comments:

 
Links :
ICB
NICE
SPC
Indication :
Status :
Red
Formulations :
  • Not Specified
Restrictions / Comments:

Important
NHS England - specialist centres only
 
Links :
NHSE
SPC
Indication :
Status :
Red
Formulations :
  • Depot injection
  • Subcutaneous injection (sc)
Restrictions / Comments:

Important

NHSE Specialist Centres - only commissioned from RSFT in Surrey Heartlands.
SASH - only for use under shared care arrangements with specialist centres.

 
Links :
NHSE
R
SPC
Indication :
Status :
Red
Formulations :
  • Injection
Restrictions / Comments:

 
Links :
Off Label
SPC
Indication :
Status :
Red
Formulations :
  • Subcutaneous injection (sc)
Restrictions / Comments:

Important

Prevention of complications following pancreatic surgery

 
Links :
SPC
Indication :
Status :
Red
Restrictions / Comments:

 
Links :
SPC
Indication :
Status :
Red
Formulations :
  • Subcutaneous injection (sc)
Restrictions / Comments:

Important

ASPH are the only Surrey Heartlands Trust commissioned to provide this.

 
Links :
NHSE
NICE
SPC
Indication :
Status :
Green
Formulations :
  • Tablets
Restrictions / Comments:

Important
Restricted Use - for use when indicated by local trust antimicrobial guidelines or specialist microbiology recommendation.
 
Links :
R
SPC
Status :
Blue
Formulations :
  • Oro-dispersible tablets
  • Tablets
Restrictions / Comments:

Important

Off-label use. On recommendation of palliative care team.

 
Links :
Off Label
SPC
Status :
Blue
Formulations :
  • Oro-dispersible tablets
  • Tablets
Restrictions / Comments:

Important

Initiation by a mental health specialist and stabilisation for at least 3 months before any request to transfer prescribing responsibility.

 
Links :
Guidelines
Off Label
SPC
Status :
Blue
Formulations :
  • Tablets
Restrictions / Comments:

Important

For the prevention of recurrence in bipolar disorder.

Initiation by a SABP specialist and stabilisation for a minimum of 3 months before any request to transfer prescribing responsibility.

 
Links :
Status :
Blue
Formulations :
  • Oro-dispersible tablets
Restrictions / Comments:

Important

For the prevention of recurrence in bipolar disorder.

Initiation by a SABP specilalist and stabilisation for a minimum of 3 months before any request to transfer prescribing responsibility.

Reserve orodispersible tablets for patients with swallowing difficulties or administration via a PEG tube

 
Links :
R
SPC
Indication :
Status :
Red
Formulations :
  • Oro-dispersible tablets
  • Tablets
Restrictions / Comments:

Important

For the reduction of distress at mealtimes in anorexia nervosa.

 
Links :
Off Label
Indication :
Status :
Blue
Formulations :
  • Tablets
Restrictions / Comments:

Important

Initiation by a SABP specialist and stabilisation for a minimum of 3 months before any request to transfer prescribing responsibility.

 
Links :
Indication :
Status :
Blue
Formulations :
  • Oro-dispersible tablets
Restrictions / Comments:

Important

Initiation by a SABP specialist and stabilisation for a minimum of 3 months before any request to transfer prescribing responsibility.

Reserve orodispersible tablets for patients with swallowing difficulties or administration via a PEG tube

 
Links :
R
SPC
Status :
Red
Formulations :
  • Oro-dispersible tablets
  • Tablets
Restrictions / Comments:

Important
Off-label use.
 
Links :
Off Label
SPC
Status :
Blue
Formulations :
  • Oro-dispersible tablets
Restrictions / Comments:

Important

Off-label use. Primary care prescribing on request of specialist palliative care team.

 
Links :
Off Label
SPC
Status :
Red
Formulations :
  • Subcutaneous injection (sc)
Restrictions / Comments:

Important

Off-label use. Primary care prescribing on request of specialist palliative care team.

Off-label use.

 
Links :
Off Label
SPC
Status :
Non Formulary
Formulations :
  • Not Specified
Restrictions / Comments:

 
Links :
NFD1
SPC
Indication :
Status :
Red
Formulations :
  • Injection
Restrictions / Comments:

Important

Off-label use.

 
Links :
Off Label
SPC
Status :
Blue
Formulations :
  • Tablets
Restrictions / Comments:

Important

Initiation by a SABP specialist and stabilisation for a minimum of 3 months before any request to transfer prescribing responsibility.

 
Links :
SPC
Status :
Blue
Formulations :
  • Oro-dispersible tablets
Restrictions / Comments:

Important

Reserve orodispersible tablets for patients with swallowing difficulties or administration via a PEG tube

Initiation by a SABP specialist and stabilisation for a minimum of 3 months before any request to transfer prescribing responsibility.

 
Links :
R
SPC
Status :
Red
Formulations :
  • Depot injection
Restrictions / Comments:

Important

Olanzapine embonate - maintenance in schizophrenia.
Not suitable for  administration under the locally commissioned service (LCS).
Note 3 hour monitoring after dose .

 
Links :
SPC
Indication :
Status :
Green
Formulations :
  • Ear drops
Restrictions / Comments:

Important
Available to purchase for self care.
 
Links :
SPC
Indication :
Status :
Green
Formulations :
  • Tablets
Restrictions / Comments:

 
Links :
Status :
Non Formulary
Formulations :
  • Soft mist inhaler
Restrictions / Comments:

Important

LABA monotherapy no longer recommended for asthma or COPD.

Not for initiation in new patients.

 
Links :
Status :
Green (see narrative)
Formulations :
  • Eye drops
Restrictions / Comments:

Important

Prescribe generically.

Sodium cromoglycate 2% or Antazoline with Xylometazoline (Otrivine-Antistin) are the preferred antihistamine/anti-inflammatory eye drops Olopatidine licensed from 3 years of age.
 
Links :
SPC
Status :
Non Formulary
Formulations :
  • Capsules
  • Tablets
Restrictions / Comments:

Important

Licensed in mild ulcerative colitis

 
Links :
Status :
Red
Formulations :
  • Not Specified
Restrictions / Comments:

Important
Service not currently provided by any Surrey Heartlands Trusts
 
Links :
NHSE
NICE
SPC
Indication :
Status :
Non Formulary
Formulations :
  • Not Specified
Restrictions / Comments:

Important

Treatment resistant psychosis.

 
Links :
NFD1
SPC
Indication :
Status :
Red
Formulations :
  • Capsules
Restrictions / Comments:

Important
Prescribing in Primary Care may continue for existing patients under certain circumstances whilst waiting for specialist review. Please see PAD for detail
 
Links :
SPC
Status :
Green
Formulations :
  • Capsules
Restrictions / Comments:

Important
Preferred
1st line for patients with no swallowing difficulties.
 
Links :
Status :
Non Formulary
Formulations :
  • Tablets
Restrictions / Comments:

Important
Omeprazole or lansoprazole capsules are 1st-line. Pantoprazole or rabeprazole tablets are 2nd-line for patients without swallowing difficulties (suitable for patients that cannot have animal-derived products).
 
Links :
Status :
Non Formulary
Formulations :
  • Oral suspension
  • Oro-dispersible tablets
Restrictions / Comments:

Important
Omeprazole capsules can be opened for patients with swallowing difficulties. Lansoprazole oro-dispersible tablets are 1st-line for patients with enteral feeding tubes
 
Links :
Status :
Green
Formulations :
  • Capsules
Restrictions / Comments:

Important
Preferred
1st line option in children who are able to swallow capsules. Most capsules can also be opened and mixed with water or fruit juice (licensed).
 
Links :
Status :
Green (see narrative)
Formulations :
  • Dispersible tablets
Restrictions / Comments:

Important
Mezzopram is the preferred brand - smaller granule size. Omeprazole MUPS is an alternative. Disperse in water then mix with juice, apple sauce or yoghurt
 
Links :
Status :
Blue
Formulations :
  • Oral suspension
Restrictions / Comments:

Important
Only for children under 10kg and/or with a feeding tube less than 8Fr
 
Links :
Status :
Red
Formulations :
  • Powder
Restrictions / Comments:

Important
Aclomep powder - ASPH NICU only
 
Links :
Status :
Non Formulary
Formulations :
  • Tablets
Restrictions / Comments:

 
Links :
Status :
Red
Formulations :
  • Intravenous infusion
Restrictions / Comments:

Important
ASPH use pantoprazole IV 1st-line
 
Links :
SPC
Indication :
Status :
Red
Formulations :
  • Intravenous infusion
Restrictions / Comments:

Important
ASPH use pantoprazole IV 1st-line
 
Links :
SPC
Status :
Red
Formulations :
  • Intravenous infusion
Restrictions / Comments:

 
Links :
Off Label
SPC
Status :
Red
Formulations :
  • Intravenous infusion
Restrictions / Comments:

Important
ASPH use pantoprazole IV 1st-line
 
Links :
SPC
Indication :
Status :
Red
Formulations :
  • Injection
  • Oral solution
  • Tablets
Restrictions / Comments:

Important
Non-specific nausea / vomiting. See separate entries for pregnancy, post-operative and chemo-related indications.
Off-label use. Only licensed for post-operative and chemotherapy-induced nausea and vomiting
 
Links :
Off Label
SPC
Indication :
Status :
Red
Formulations :
  • Oro-dispersible tablets
  • Orodispersible films
Restrictions / Comments:

Important
Non-specific nausea / vomiting. See separate entries for pregnancy, post-operative and chemo-related indications.
Orodispersible preparations reserved for use when ordinary tablets are not suitable.
 
Links :
Off Label
SPC
Status :
Blue
Formulations :
  • Oral solution
  • Tablets
Restrictions / Comments:

Important
Oral solution reserved for use when tablets are not suitable. On request from the specialist / Cancer Centre
 
Links :
SPC
Status :
Blue
Formulations :
  • Oro-dispersible tablets
  • Orodispersible films
Restrictions / Comments:

Important
Orodispersible preparations reserved for use when ordinary tablets are not suitable. On request from the specialist / Cancer Centre
 
Links :
SPC
Status :
Red
Formulations :
  • Injection
Restrictions / Comments:

 
Links :
SPC
Status :
Blue
Formulations :
  • Injection
  • Oral solution
  • Oro-dispersible tablets
  • Tablets
Restrictions / Comments:

Important

Off-label use. On recommendation of palliative care team

 
Links :
Off Label
SPC
Status :
Red
Formulations :
  • Injection
  • Oral solution
  • Tablets
Restrictions / Comments:

Important
Oral solution reserved for use when tablets are not suitable.
 
Links :
SPC
Status :
Red
Formulations :
  • Oro-dispersible tablets
  • Orodispersible films
Restrictions / Comments:

Important
Orodispersible preparations reserved for use when ordinary tablets are not suitable.
 
Links :
SPC
Status :
Red
Formulations :
  • Suppositories
Restrictions / Comments:

 
Links :
SPC
Status :
Green (see narrative)
Formulations :
  • Tablets
Restrictions / Comments:

Important
2nd line treatment option. Should not be prescribed for longer than 5 days and not recommended in the first trimester.
 
Links :
Guidelines
Off Label
R
SPC
Status :
Green (see narrative)
Formulations :
  • Orodispersible films
Restrictions / Comments:

Important
An option in patients with swallowing difficulties. 2nd line treatment option. Should not be prescribed for longer than 5 days and not recommended in the first trimester.
 
Links :
Guidelines
Off Label
R
SPC
Status :
Non Formulary
Formulations :
  • Oral solution
  • Oro-dispersible tablets
Restrictions / Comments:

Important

Orodispersible films are a more cost effective option than oral solution and orodispersible tablets.

 
Links :
Indication :
Status :
Blue
Formulations :
  • Capsules
Restrictions / Comments:

Important
2nd line COMT inhibitor. Entacapone is the locally agreed 1st-line choice
 
Links :
Status :
Red
Formulations :
  • Not Specified
Restrictions / Comments:

 
Links :
SPC
Indication :
Status :
Blue
Formulations :
  • Eye drops
Restrictions / Comments:

Important
Severe dry eye
Prescribe by brand. Prescribe on specialist initiation
 
Links :
Status :
Blue
Formulations :
  • Oromucosal gel
Restrictions / Comments:

Important

Oncology request only. Primary Care prescribing may be appropriate in longer-term use and on request from oncology specialist team only. Ongoing use should be reviewed regularly to ensure that therapy is still required.

 
Links :
SPC
Indication :
Status :
Green
Formulations :
  • Sachets (powder)
Restrictions / Comments:

Important

Dioraltye Natural 

 
Links :
SPC
Indication :
Status :
Green
Formulations :
  • Sachets (powder)
Restrictions / Comments:

Important

Dioralyte Blackcurrant

 
Links :
SPC
Indication :
Status :
Green
Formulations :
  • Sachets (powder)
Restrictions / Comments:

Important

Dioarlyte relief blackcurrant

 
Links :
SPC
Status :
Green
Formulations :
  • Capsules
Restrictions / Comments:

 
Links :
SPC
Status :
Non Formulary
Restrictions / Comments:

 
Links :
NFD1
Indication :
Status :
Non Formulary
Formulations :
  • Not Specified
Restrictions / Comments:

 
Links :
NFD1
SPC
Indication :
Status :
See narrative
Formulations :
  • Device
Restrictions / Comments:

Important

This device has not been assessed for inclusion on the formulary. Contact your pharmacy team for advice on making an application to APC.

 
Links :
NFD2
SPC
Indication :
Status :
Green
Formulations :
  • Oral solution
  • Oral suspension
  • Tablets
Restrictions / Comments:

Important

recommended for  treatment of influenza in adults and children meeting the criteria set out in NICE TA 168 and for prophylaxis of influenza in adults and children meeting the criteria set out in NICE TA 158

 
Links :
70. Osmolite
Drug:
Osmolite
(Adult enteral feeds)
Status :
Blue
Formulations :
  • Liquid
Restrictions / Comments:

Important

Enteral feeds should NOT be prescribed in primary care in Guildford and Waverley or North West Surrey. In Surrey Downs and East Surrey prescribe on request from specialist dietitian 

 
Links :
71. Osmolite 1.5
Drug:
Osmolite 1.5
(Adult enteral feeds)
Status :
Blue
Formulations :
  • Liquid
Restrictions / Comments:

Important

Enteral feeds should NOT be prescribed in primary care in Guildford and Waverley or North West Surrey. In Surrey Downs and East Surrey prescribe on request from specialist dietitian 

 
Links :
72. Osmolite HP
Drug:
Osmolite HP
(Adult enteral feeds)
Status :
Blue
Formulations :
  • Liquid
Restrictions / Comments:

Important

Enteral feeds should NOT be prescribed in primary care in Guildford and Waverley or North West Surrey. In Surrey Downs and East Surrey prescribe on request from specialist dietitian 

 
Links :
73. Osmolite Plus
Drug:
Osmolite Plus
(Adult enteral feeds)
Status :
Blue
Formulations :
  • Liquid
Restrictions / Comments:

Important

Enteral feeds should NOT be prescribed in primary care in Guildford and Waverley or North West Surrey. In Surrey Downs and East Surrey prescribe on request from specialist dietitian 

 
Links :
Indication :
Status :
Blue
Formulations :
  • Tablets
Restrictions / Comments:

Important
Initiation in primary care following specialist recommendation. Reserve for severe dryness or when other treatments are ineffective / contraindicated.
 
Links :
R
SPC
Indication :
Status :
Blue
Formulations :
  • Oral suspension
  • Tablets
Restrictions / Comments:

 
Links :
SPC
Status :
Red
Formulations :
  • Eye drops (preservative free
  • unit dose)
Restrictions / Comments:

Important
0.4% preservative free eye drops
 
Links :
SPC
Indication :
Status :
Blue
Formulations :
  • Capsules
  • Capsules (slow release)
  • Tablets
  • Tablets (slow release)
Restrictions / Comments:

Important
On recommendation from specialist team. Modified release may be used for patients with intolerable side effects to IR formulation
 
Links :
SPC
Indication :
Status :
Non Formulary
Formulations :
  • Elixir
  • Liquid
  • Oral solution
  • Oral suspension
  • Patches
Restrictions / Comments:

 
Links :
NFD1
SPC
Status :
Green (see narrative)
Formulations :
  • Patches
Restrictions / Comments:

Important
Solifenacin 1mg/ml oral SUSPENSION is preferred for patients with swallowing difficulties. Oxybutynin patches are reserved for patients where an oral formulation is not suitable
 
Links :
Status :
Non Formulary
Formulations :
  • Modified release tablets
  • Oral solution
  • Tablets
Restrictions / Comments:

Important
Switch to solifenacin recommended (if appropriate).
 
Links :
Status :
See narrative
Formulations :
  • Intravesical
Restrictions / Comments:

Important

This drug has not yet been assessed for inclusion on the formulary. Contact your pharmacy team for advice on making an application to the APC.

 
Links :
Indication :
Status :
Green (see narrative)
Formulations :
  • Capsules
  • Oral solution
Restrictions / Comments:

Important
For patients unable to tolerate / poor response to morphine. Modified-release preparations to be prescribed by brand
 
Links :
Indication :
Status :
Green (see narrative)
Formulations :
  • Modified release tablets
Restrictions / Comments:

Important
For use in patients where morphine sulfate is not suitable / not tolerated. Modified-release preparations to be prescribed by brand
 
Links :
Indication :
Status :
Red
Formulations :
  • Injection
Restrictions / Comments:

Important
Alternative for patients unable to tolerate / poor response to morphine. Care with dose conversion.
 
Links :
Indication :
Status :
Green
Formulations :
  • Injection
Restrictions / Comments:

 
Links :
CD
SPC
Indication :
Status :
Green (see narrative)
Formulations :
  • Capsules
  • Oral solution
Restrictions / Comments:

Important

For patients unable to tolerate / poor response to morphine.

 
Links :
CD
SPC
Indication :
Status :
Green (see narrative)
Formulations :
  • Modified release tablets
Restrictions / Comments:

Important

For use in patients where morphine sulfate is not suitable / not tolerated.

Modified-release preparations to be prescribed by brand

 
Links :
CD
SPC
Indication :
Status :
Non Formulary
Formulations :
  • Not Specified
Restrictions / Comments:

 
Links :
Guidelines
CD
NFD2
SPC
Indication :
Status :
Non Formulary
Restrictions / Comments:

 
Links :
NFD2
SPC
Indication :
Status :
Green
Formulations :
  • Tablets
Restrictions / Comments:

Important
NICE condensed summary table of antimicrobial guidance or specialist microbiology recommendation
 
Links :
SPC
Indication :
Status :
Green
Formulations :
  • Tablets
Restrictions / Comments:

Important
NICE condensed summary table of antimicrobial guidance or specialist microbiology recommendation
 
Links :
SPC
Indication :
Status :
Red
Restrictions / Comments:

 
Links :
SPC
Status :
Red
Formulations :
  • Intramuscular injection (IM)
Restrictions / Comments:

 
Links :
SPC
Status :
Red
Formulations :
  • Intravenous infusion
Restrictions / Comments:

 
Links :
SPC
Status :
Red
Formulations :
  • Capsules
Restrictions / Comments:

Important
Ulcerative Colitis - adults only.
 
Links :
Indication :
Status :
Red
Formulations :
  • Capsules
Restrictions / Comments:

 
Links :
NHSE
SPC